Text Size
Trial record 1 of 1135 for:    "Parkinson's Disease "
Previous Study | Return to List | Next Study

Nocturnal Parkinson's Disease Symptoms Study Group

This study is currently recruiting participants.
Verified April 2013 by Chulalongkorn University
Sponsor:
Information provided by (Responsible Party):
Roongroj Bhidayasiri, Chulalongkorn University
ClinicalTrials.gov Identifier:
NCT01662427
First received: August 7, 2012
Last updated: April 9, 2013
Last verified: April 2013
History of Changes
  Purpose

To study associate factor of Noctural Parkinson's Disease Symptoms and quality of life in Parkinson's disease patients and caregivers.


Condition Intervention
Parkinson's Disease
 Other: Questionaire to assess Noctural Parkinson's Disease Symptoms

Study Type: Interventional
Study Design: Primary Purpose: Screening
Official Title: Nocturnal Parkinson's Disease Symptoms Study Group

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Chulalongkorn University:

Primary Outcome Measures:
  • To assess Noctural Parkinson's Disease Symptoms [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess quality of life in Parkinson's Disease patient [ Designated as safety issue: No ]
  • To assess quality of life in caregiver of Parkinson's Disease patient [ Designated as safety issue: No ]

Study Start Date: November 2012
Arms Assigned Interventions
Questionniare Other: Questionaire to assess Noctural Parkinson's Disease Symptoms
Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life

  Eligibility

Ages Eligible for Study:   30 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Idiopathic Parkinson's disease patient

Exclusion Criteria:

  1. Patient with Secondary Parkinsonism eg.Drug-induced Parkinsonism, Vascular Parkinsonism, exposure to toxin, Encephalitis
  2. Patient with Atypical Parkinsonial Syndromes eg. Parkinson-plus syndrome, Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
  3. Patient with Heredodegenerative parkinsonism eg. Spinocerebellar ataxias, Wilson's disease, Juvenile Huntington's disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01662427

Contacts
Contact: Roongroj Bhidayasiri, MD +662 2564630 rbh1@ucla.edu

Locations
Thailand
Roongroj Bhidayasiri Recruiting
Pathumwan, Bangkok, Thailand, 10330
Contact: Roongroj Bhidayasiri, MD     +662 2564630     rbh1@ucla.du    
Sponsors and Collaborators
Chulalongkorn University
  More Information

No publications provided

Responsible Party: Roongroj Bhidayasiri, Associate Professor, Chulalongkorn University
ClinicalTrials.gov Identifier: NCT01662427     History of Changes
Other Study ID Numbers: 6222012
Study First Received: August 7, 2012
Last Updated: April 9, 2013
Health Authority: Thailand: Ethical Committee

Keywords provided by Chulalongkorn University:
Quality of life
Noctural Parkinson's Disease Symptoms

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
 Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on May 23, 2013